Navigation Links
Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects
Date:6/27/2011

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of LeukotheraTM, a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.

The outcome of these in vitro experiments demonstrated that combining LeukotheraTM with such widely employed drugs as etoposide, mitoxantrone, daunorubicin, busulfan and imatinib killed leukemia cells much more effectively than when the agents were used alone.  LeukotheraTM is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

Dr. Scott Kachlany, founder of Actinobac Biomed, explained. "Drug combination therapies for cancer are now frequently considered by oncologists due to their many advantages, which include the possibility of reducing doses of toxic chemotherapeutic agents and a lower chance of developing drug resistance," he said.  "The biological mechanism of LeukotheraTM differs from that of other cancer drugs so including it to blood cancer treatment protocols may be a highly effective strategy."

Actinobac Biomed, Inc. was founded in 2009 with financial backing from Foundation Venture Capital Group, LLC, to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey.  The company has exclusively licensed the rights to develop LeukotheraTM as a therapeutic agent for the treatment of hematologic malignancies, autoimmune and inflammatory diseases and HIV infection.

"We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that can make a huge difference for people suffering with leukemia and other diseases," said James M. Golubieski, president of Foundation Venture Capital Group (www.foundationventure.com), an affiliate of New Jersey Health Foundation.  

For more information about Foundation Venture Capital Group, contact Jim Golubieski at (908) 731-6601 or jgolubieski@njhf.org.

For more information or to explore ways in which to partner with Actinobac, contact them at (732) 371-2694, info@actinobac.com or visit www.actinobac.com.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
3. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
4. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
5. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
6. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
7. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
8. In a New Audio Interview at SmallCapVoice.com, Gerard Dab, Chairman and CEO of Visual Healthcare Corp., Provides Details Regarding Recent News
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
11. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
Breaking Medicine News(10 mins):